美国医药开发外包市场规模、份额、趋势分析报告：按服务、配方、治疗领域、最终用途、地区、细分市场预测，2025-2030 年

市场规模与趋势：

预计 2024 年美国配方开发外包市场规模将达到 88.7 亿美元，2025 年至 2030 年的复合年增长率将达到 8.3%。

这一增长的驱动力源于对创新型医药和生物技术产品日益增长的需求、不断上涨的研发成本以及对专业知识的需求。对于希望简化研发流程、降低成本并取得更广泛资源的公司而言，外包配方开发是个相当吸引人的选择。

製药和生技公司研发投入的激增是推动製剂开发外包服务需求成长的主要因素。过去二十年，研发支出和新药上市数量不断增加，透过外包可以节省成本并加快流程。这种日益增长的需求促使合约服务提供者拓展其能力，从而刺激了美国製剂开发外包产业的成长。因此，这些因素对市场扩张做出了重大贡献。

药物配方成本高、耗时耗力，严重依赖试验来预测最佳配方。估算最佳配方对于满足医药市场对新型活性药物原料药(API) 的需求以及降低整体医疗保健成本至关重要。这有助于业界找到高效的药物开发方法。因此，製药和生物技术行业广泛将这些服务委託给契约製造製造商，以简化成本和流程。

技术创新的动力促使企业投资发现新化合物和开发重磅药物，导致学名药製造商增加，并且由于用于治疗未满足的医疗需求和罕见疾病的药物的研发活动不断增加，医药市场也不断扩大。

美国医药开发外包报告细分

该报告提供了2018年至2030年各国收益成长预测，并分析了各细分领域的最新产业趋势。在本研究中，Grand View Research根据服务、配方、治疗领域和最终用途对美国医药开发外包市场进行了细分：

• 服务业展望（销售额，2018-2030）
• 预配方
• 配方开发
• 配方展望（销售额，2018-2030）
• 口服
• 注射
• 局部药物
• 其他的
• 治疗领域展望（销售额，2018-2030）
• 肿瘤学
• 感染疾病
• 神经病学
• 血液学
• 呼吸系统
• 心血管
• 皮肤科
• 其他的
• 最终用途展望（销售额，2018-2030）
• 製药和生物製药公司
• 政府和学术机构
• 其他的

目录

第一章调查方法与范围

第二章执行摘要

第三章美国製药开发外包市场变数、趋势与范围

• 市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 商业环境分析
  • 产业分析-波特五力分析
  • PESTLE分析

第四章美国製药开发外包市场：服务分析

• 2024年及2030年服务市场占有率
• 服务细分仪表板
• 市场规模、预测与趋势分析（按服务，2018-2030 年）
• 处方前
• 配方开发

第五章美国製药开发外包市场：配方分析

• 2024年及2030年的医药市场占有率
• 处方细分细分仪表板
• 2018 年至 2030 年市场规模、预测与趋势分析（按配方）
• 口服
• 注射
• 话题
• 其他的

第六章美国治疗领域开发外包市场：治疗领域分析

• 2024 年和 2030 年治疗领域市场占有率
• 治疗领域细分仪表板
• 按治疗领域分類的市场规模、预测和趋势分析（2018-2030 年）
• 肿瘤学
• 感染疾病
• 神经病学
• 血液学
• 呼吸系统
• 心血管系统
• 皮肤科
• 其他的

第七章美国配方开发外包市场：最终用途分析

• 2024 年及 2030 年最终用途市场占有率
• 最终用途细分仪表板
• 按最终用途分類的市场规模、预测和趋势分析（2018-2030 年）
• 製药和生物製药公司
• 政府和学术机构
• 其他的

第八章 竞争态势

• 参与者概览
• 企业市场分析
• 公司分类
• 战略地图
• 公司简介/上市公司
  • SGS Societe Generale de Surveillance SA
  • Intertek Group plc
  • Recipharm AB
  • Lonza
  • Charles River Laboratories
  • Eurofins Scientific
  • Element
  • Labcorp
  • Thermo Fisher Scientific Inc
  • Catalent, Inc

Market Size & Trends:

The U.S. formulation development outsourcing market size was estimated at USD 8.87 billion in 2024 and is projected to grow at a CAGR of 8.3% from 2025 to 2030. This growth is driven by increasing demand for innovative pharmaceutical and biotech products, rising R&D costs, and a need for specialized expertise. Outsourcing formulation development is an attractive option for companies looking to streamline their R&D processes, reduce costs, and access a wider range of resources.

The surge in R&D by pharmaceutical and biotechnology firms is a major driver propelling the demand for outsourced formulation development services. Over the past two decades, R&D spending and new drug launches have increased, leading to cost reduction and accelerated processes through outsourcing. This rising demand has prompted contract service providers to expand their capacities, fostering the growth of the U.S. formulation development outsourcing industry. Consequently, these factors substantially contribute to market expansion.

Drug formulation relies heavily on trial-and-error methods to predict optimal formulations, which can be costly, time-consuming, and labor-intensive. To address the need for reducing expenses on new Active Pharmaceutical Ingredients (APIs) and overall healthcare costs in the pharmaceuticals market, it is crucial to estimate preferred formulations. This helps the industry identify efficient drug development approaches. Consequently, the pharmaceutical and biotechnology sector extensively outsources these services to contract manufacturers to streamline costs and processes.

Advancements in technology drive innovations encourage companies to invest in discovering new compounds and developing blockbuster drugs. This leads to an increase in generic manufacturers and a growing pharmaceutical market, driven by unmet needs for various disorders and rising R&D activities for orphan therapies.

U.S. Formulation Development Outsourcing Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. formulation development outsourcing market report based on service, formulation, therapeutic area, and end use:

• Service Outlook (Revenue, USD Million; 2018 - 2030)
• Pre-formulation
• Formulation Development
• Formulation Outlook (Revenue, USD Million; 2018 - 2030)
• Oral
• Injectable
• Topical
• Others
• Therapeutic Area Outlook (Revenue, USD Million; 2018 - 2030)
• Oncology
• Infectious Disease
• Neurology
• Hematology
• Respiratory
• Cardiovascular
• Dermatology
• Others
• End Use Outlook (Revenue, USD Million; 2018 - 2030)
• Pharmaceutical and Biopharmaceutical Companies
• Government and Academic Institutes
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Formulation
  • 1.2.3. Therapeutic Area
  • 1.2.4. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Formulation Development Outsourcing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Formulation Development Outsourcing Market: Service Business Analysis

• 4.1. Service Market Share, 2024 & 2030
• 4.2. Service Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Service, 2018 to 2030 (USD Million)
• 4.4. Pre-formulation
  • 4.4.1. Pre-formulation Market, 2018 - 2030 (USD Million)
• 4.5. Formulation Development
  • 4.5.1. Formulation Development Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Formulation Development Outsourcing Market: Formulation Business Analysis

• 5.1. Formulation Market Share, 2024 & 2030
• 5.2. Formulation Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Formulation, 2018 to 2030 (USD Million)
• 5.4. Oral
  • 5.4.1. Oral Formulation Market, 2018 - 2030 (USD Million)
• 5.5. Injectable
  • 5.5.1. Injectable Formulation Market, 2018 - 2030 (USD Million)
• 5.6. Topical
  • 5.6.1. Topical Formulation Market, 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Other Formulation Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Therapeutic Area Development Outsourcing Market: Therapeutic Area Business Analysis

• 6.1. Therapeutic Area Market Share, 2024 & 2030
• 6.2. Therapeutic Area Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Formulation Development Outsourcing Market, for Oncology, 2018 - 2030 (USD Million)
• 6.5. Infectious Disease
  • 6.5.1. Formulation Development Outsourcing Market, for Infectious Disease, 2018 - 2030 (USD Million)
• 6.6. Neurology
  • 6.6.1. Formulation Development Outsourcing Market, for Neurology, 2018 - 2030 (USD Million)
• 6.7. Hematology
  • 6.7.1. Formulation Development Outsourcing Market, for Hematology, 2018 - 2030 (USD Million)
• 6.8. Respiratory
  • 6.8.1. Formulation Development Outsourcing Market, for Respiratory, 2018 - 2030 (USD Million)
• 6.9. Cardiovascular
  • 6.9.1. Formulation Development Outsourcing Market, for Cardiovascular, 2018 - 2030 (USD Million)
• 6.10. Dermatology
  • 6.10.1. Formulation Development Outsourcing Market, for Dermatology, 2018 - 2030 (USD Million)
• 6.11. Others
  • 6.11.1. Formulation Development Outsourcing Market, for Others, 2018 - 2030 (USD Million)

Chapter 7. U.S. Formulation Development Outsourcing Market: End Use Business Analysis

• 7.1. End Use Market Share, 2024 & 2030
• 7.2. End Use Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Pharmaceutical and Biopharmaceutical Companies
  • 7.4.1. Pharmaceutical and Biopharmaceutical Companies Segment Market, 2018 - 2030 (USD Million)
• 7.5. Government and Academic Institutes
  • 7.5.1. Government and Academic Institutes Segment Market, 2018 - 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Segment Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. SGS Societe Generale de Surveillance SA
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Intertek Group plc
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Recipharm AB
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Lonza
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Charles River Laboratories
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Eurofins Scientific
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Element
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Labcorp
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Thermo Fisher Scientific Inc
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Catalent, Inc
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. U.S. formulation development outsourcing market, by service, 2018 - 2030 (USD Million)
• Table 4. U.S. formulation development outsourcing market, by formulation, 2018 - 2030 (USD Million)
• Table 5. U.S. formulation development outsourcing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 6. U.S. formulation development outsourcing market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 U.S. formulation development outsourcing market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Service outlook (USD Million)
• Fig. 10 Formulation outlook (USD Million)
• Fig. 11 Therapeutic area outlook (USD Million)
• Fig. 12 End use outlook (USD Million)
• Fig. 13 Competitive landscape
• Fig. 14 U.S. formulation development outsourcing market dynamics
• Fig. 15 U.S. formulation development outsourcing market: Porter's five forces analysis
• Fig. 16 U.S. formulation development outsourcing market: Pestle analysis
• Fig. 17 U.S. formulation development outsourcing market: Service segment dashboard
• Fig. 18 U.S. formulation development outsourcing market: Service market share analysis, 2024 & 2030
• Fig. 19 Pre-formulation market, 2018 - 2030 (USD Million)
• Fig. 20 Formulation development market, 2018 - 2030 (USD Million)
• Fig. 21 U.S. formulation development outsourcing market: Formulation segment dashboard
• Fig. 22 U.S. formulation development outsourcing market: Formulation market share analysis, 2024 & 2030
• Fig. 23 Oral formulation market, 2018 - 2030 (USD Million)
• Fig. 24 Injectable formulation market, 2018 - 2030 (USD Million)
• Fig. 25 Topical formulation market, 2018 - 2030 (USD Million)
• Fig. 26 Other formulation market, 2018 - 2030 (USD Million)
• Fig. 27 U.S. formulation development outsourcing market: Therapeutic area segment dashboard
• Fig. 28 U.S. formulation development outsourcing market: Therapeutic area market share analysis, 2024 & 2030
• Fig. 29 Formulation development outsourcing market, for Oncology, 2018 - 2030 (USD Million)
• Fig. 30 Formulation development outsourcing market, for Infectious Disease, 2018 - 2030 (USD Million)
• Fig. 31 Formulation development outsourcing market, for Neurology 2018 - 2030 (USD Million)
• Fig. 32 Formulation development outsourcing market, for Hematology, 2018 - 2030 (USD Million)
• Fig. 33 Formulation development outsourcing market, for Respiratory, 2018 - 2030 (USD Million)
• Fig. 34 Formulation development outsourcing market, for Cardiovascular 2018 - 2030 (USD Million)
• Fig. 35 Formulation development outsourcing market, for Dermatology, 2018 - 2030 (USD Million)
• Fig. 36 Formulation development outsourcing market, for Others, 2018 - 2030 (USD Million)
• Fig. 37 U.S. formulation development outsourcing market: End use segment dashboard
• Fig. 38 U.S. formulation development outsourcing market: End use market share analysis, 2024 & 2030
• Fig. 39 Pharmaceutical and biopharmaceutical companies segment market, 2018 - 2030 (USD Million)
• Fig. 40 Government and academic institutes segment market, 2018 - 2030 (USD Million)
• Fig. 41 Other segments market, 2018 - 2030 (USD Million)
• Fig. 42 Company categorization
• Fig. 43 Company market position analysis
• Fig. 44 Strategic framework